Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#311 of 388

Brian Abrahams

RBC Capital · Equity Research Analyst
ProvisionalRating since 2022No new ratings since Jun 2025

Analyst rating accuracy & track record

Brian Abrahams is an equity research analyst at RBC Capital. Quantellect has scored 31 of their stock calls across 9 companies. Their picks beat their sector 25% of the time over the next 12 months, and their price targets were reached 23% of the time within a year.

Win % vs sector
25%
PT Hit % (12mo)
23%
Avg sector-excess
−16.5%
Scored calls
31
Tickers
9
Tier
Provisional

Track record

Quantellect has scored 31 of Brian Abrahams's stock calls across 9 companies, dating back to 2022. Their rated stocks beat their own sector 25% of the time over the next 12 months. On a typical call, a Abrahams pick returned −16.5% more than its sector over the following year.

Of the scored calls, 31 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
BCRXBioCryst Pharmaceuticals Inc
Buy$13.00Jun 2025−6.5%Miss
MLTXMoonLake Immunotherapeutics
Buy$67.00Jun 2025−76.9%Miss
AARDAardvark Therapeutics, Inc. Common Stock
Buy$20.00May 2025−64.8%Miss
CTNMContineum Therapeutics, Inc. Class A Common Stock
Buy$31.00May 2025+279.9%Miss
XENEXenon Pharmaceuticals Inc
Buy$55.00May 2025+71.9%Hit
KPTIKaryopharm Therapeutics Inc
Buy$33.00May 2025+66.5%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$58.00May 2025+53.6%Miss
BCRXBioCryst Pharmaceuticals Inc
Buy$13.00May 2025−21.7%Miss
BCRXBioCryst Pharmaceuticals Inc
Buy$11.00Apr 2025+25.0%Hit
AARDAardvark Therapeutics, Inc. Common Stock
Buy$21.00Apr 2025−60.5%Miss
AARDAardvark Therapeutics, Inc. Common Stock
Buy$21.00Mar 2025−51.1%Miss
BCRXBioCryst Pharmaceuticals Inc
Buy$11.00Feb 2025−18.3%Hit
KPTIKaryopharm Therapeutics Inc
Buy$3.00Feb 2025−1.2%Miss
KPTIKaryopharm Therapeutics Inc
Buy$3.00Feb 2025−34.8%Miss
CTNMContineum Therapeutics, Inc. Class A Common Stock
Buy$31.00Jan 2025−44.6%Miss
NMRANeumora Therapeutics, Inc.
Buy$29.00Nov 2024−86.4%Miss
HOOKHookipa Pharma Inc
Buy$48.00Nov 2024−77.4%Miss
CTNMContineum Therapeutics, Inc. Class A Common Stock
Buy$31.00Nov 2024−39.7%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$82.00Sep 2024−29.2%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$82.00Aug 2024−71.8%Miss
CTNMContineum Therapeutics, Inc. Class A Common Stock
Buy$32.00Aug 2024−50.2%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$82.00Aug 2024−71.1%Miss
KPTIKaryopharm Therapeutics Inc
Buy$3.00Aug 2024−56.3%Miss
HOOKHookipa Pharma Inc
Buy$5.00May 2024−75.7%Miss
CTNMContineum Therapeutics, Inc. Class A Common Stock
Buy$30.00Apr 2024−74.9%Miss
HOOKHookipa Pharma Inc
Buy$5.00Mar 2024−84.2%Miss
HOOKHookipa Pharma Inc
Buy$5.00Jan 2024−73.4%Miss
HOOKHookipa Pharma Inc
Buy$7.00Sep 2023−50.2%Miss
HOOKHookipa Pharma Inc
Buy$7.00Jun 2023−38.3%Miss
HOOKHookipa Pharma Inc
Buy$7.00Nov 2022−56.8%Miss
HOOKHookipa Pharma Inc
Buy$9.00Mar 2022−52.2%Miss
Go to

Brian Abrahams: analyst track record FAQ

Is Brian Abrahams a good stock analyst?

Yes, by track record. Brian Abrahams ranks number 311 of 388 of the analysts Quantellect scores, with a Q Score of 0 out of 100. Past results do not guarantee future ones.

What is Brian Abrahams's win rate?

Brian Abrahams's win rate is 25%. Across 31 scored calls, their rated stocks beat their sector 25% of the time over the next 12 months. On a typical call they returned −16.5% more than the sector.

What stocks and sectors does Brian Abrahams cover?

Brian Abrahams covers 9 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Brian Abrahams's price targets accurate?

Brian Abrahams's price targets are reached within 12 months 23% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Brian Abrahams's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Brian Abrahams rank among Wall Street analysts?

Brian Abrahams ranks number 311 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.